Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BioMarin Pharmaceutical    BMRN

BIOMARIN PHARMACEUTICAL (BMRN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2018 09/14/2018 09/17/2018 09/18/2018 09/19/2018 Date
99.57(c) 99.41(c) 98.15(c) 99.56(c) 99.63 Last
934 216 1 298 403 1 051 267 1 277 059 332 368 Volume
+1.00% -0.16% -1.27% +1.44% +0.07% Change
More quotes
Financials (USD)
Sales 2018 1 514 M
EBIT 2018 -127 M
Net income 2018 -127 M
Finance 2018 49,2 M
Yield 2018 -
Sales 2019 1 744 M
EBIT 2019 18,7 M
Net income 2019 16,3 M
Finance 2019 33,7 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 1 722,49
EV / Sales2018 11,6x
EV / Sales2019 10,1x
Capitalization 17 681 M
More Financials
Company
BioMarin Pharmaceutical, Inc. is a biotechnology company, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.Its products include BioMarin, Brineura, Firdapse, Kuvan, Naglazyme, and Vimizim.The company was founded by... 
Sector
Pharmaceuticals
Calendar
09/27Presentation
More about the company
Surperformance© ratings of BioMarin Pharmaceutical
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOMARIN PHARMACEUTICAL
02:31pBIOMARIN PHARMACEUTICAL : to Participate in Two Investor Conferences in October
PR
09/07BIOMARIN PHARMACEUTICAL : Announces 20 Poster Presentations at Society for the S..
AQ
09/05BIOMARIN PHARMACEUTICAL : Announces 20 Poster Presentations at Society for the S..
PR
08/22BIOMARIN PHARMACEUTICAL : to Participate in Three Investor Conferences in Septem..
PR
08/16Express Scripts wants blood disorder gene therapies exclusively
AQ
08/08BIOMARIN PHARMACEUTICAL : Announces Second Quarter 2018 Results
AQ
08/07NASDAQ 100 MOVERS : Xray, bmrn
AQ
08/04BIOMARIN PHARMACEUTICAL : Dips On Mixed Second Quarter But Sales Outlook In Line
AQ
08/03BIOMARIN PHARMACEUTICAL : Management's Discussion and Analysis of Financial Cond..
AQ
08/02BIOMARIN : 2Q Earnings Snapshot
AQ
More news
Sector news : Biopharmaceuticals
03:31pGerman chemical industry warns against disruptive no-deal Brexit
RE
02:12pNOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
01:44pGILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
08:15aSHIRE : Rule 2.9 Announcement
DJ
08:03aAstraZeneca plots China robot offensive to counter price cuts
RE
More sector news : Biopharmaceuticals
Latest Tweets
09/18Richard A. Meier Sells 3,000 Shares of BioMarin Pharmaceutical Inc. $BMRN Sto.. 
09/18BioMarin Pharmaceutical Inc. $BMRN EVP George Eric Davis Sells 12,000 Shares .. 
09/12Want automatic email alerts for $STAG $PLUG $BMRN $KEY $VTGN? Subscribe to Ma.. 
09/11BioMarin Pharmaceutical Inc. $BMRN Receives $117.00 Average Target Price from.. 
09/09Insider Selling: BioMarin Pharmaceutical Inc. $BMRN Director Sells 1,000 Shar.. 
More tweets
Qtime:98
News from SeekingAlpha
09/07Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update 
09/06Biotechs and biopharmas in the red 
09/05Gene therapy players under pressure 
08/30FDA OK's Bayer's Jivi for hemophilia A 
08/27Ultragenyx's Mepsevii OK'd in Europe for MPS VII 
Chart BIOMARIN PHARMACEUTICAL
Duration : Period :
BioMarin Pharmaceutical Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMARIN PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 119 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Daniel K. Spiegelman Chief Financial Officer & Executive Vice President
Eduardo E. Von Pervieux Chief Information Officer & Vice President
Leonard E. Post Chief Scientific Officer
Geoffrey M. Nichol Senior Vice President & Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BIOMARIN PHARMACEUTICAL10.07%17 430
CSL LIMITED45.29%67 397
BIOGEN5.75%67 362
ALEXION PHARMACEUTICALS1.03%26 255
GRIFOLS-0.31%17 130
CELLTRION HEALTHCARE CO LTD--.--%12 367